Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00793741 · ClinicalTrials.gov registry record
Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 19
- Enrollment target
NCT00793741: Completed study, sponsored by University of Minnesota.
NCT00793741 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00793741 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether islet transplantation alters brain glucose concentrations in patients with type 1 diabetes, recurrent hypoglycemia, and hypoglycemia unawareness when compared to that measured prior to transplant in the same subjects.
Interventions
- DRUG somatostatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-12 |
| Est. Completion | 2017-03 |
What the finished NCT00793741 record still lists
NCT00793741 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which somatostatin is the first listed.
NCT00793741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00793741 about?
NCT00793741 is a clinical study titled "Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness". The purpose of this study is to determine whether islet transplantation alters brain glucose concentrations in patients with type 1 diabetes, recurrent hypoglycemia, and hypoglycemia unawareness when compared to that measured prior to transplant in the same subjects.
What is the current status of trial NCT00793741?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2007-12. Estimated completion is 2017-03.
What interventions are being tested in trial NCT00793741?
The interventions under investigation include: somatostatin (DRUG).
Who is sponsoring clinical trial NCT00793741?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia